| scholarly article | Q13442814 |
| P50 | author | Raymond J. Pickles | Q114519286 |
| P2093 | author name string | Edward Walsh | |
| Liqun Zhang | |||
| Mark E Peeples | |||
| Rachael M Liesman | |||
| Steven Kwilas | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection | Q28138786 | ||
| Animal cell mutants defective in glycosaminoglycan biosynthesis | Q28305815 | ||
| Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins | Q45832170 | ||
| Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins | Q45846968 | ||
| Respiratory syncytial virus proteins | Q45886355 | ||
| Well-differentiated human airway epithelial cell cultures. | Q47910046 | ||
| A highly efficient procedure for site-specific mutagenesis of full-length plasmids using Vent DNA polymerase. | Q54600380 | ||
| Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites | Q29615170 | ||
| Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant | Q33738521 | ||
| Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection | Q33787265 | ||
| Respiratory syncytial virus infection in adults | Q33961877 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins | Q34337480 | ||
| Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology | Q34364942 | ||
| Respiratory syncytial virus: reverse genetics and vaccine strategies | Q34690910 | ||
| Function of the respiratory syncytial virus small hydrophobic protein | Q35947557 | ||
| New generation live vaccines against human respiratory syncytial virus designed by reverse genetics | Q36237057 | ||
| Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | Q36280388 | ||
| Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein | Q36486699 | ||
| Polypeptides of respiratory syncytial virus | Q36512580 | ||
| Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. | Q36831654 | ||
| Respiratory syncytial virus infection in mice | Q37099153 | ||
| Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine | Q37208256 | ||
| Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium | Q37743793 | ||
| The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate | Q39592019 | ||
| Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. | Q39595322 | ||
| Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene | Q39603697 | ||
| Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. | Q40130924 | ||
| Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy | Q40614352 | ||
| Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus | Q40732224 | ||
| Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. | Q40847983 | ||
| An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
| Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells | Q41138783 | ||
| Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. | Q41184833 | ||
| Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus | Q41346333 | ||
| Respiratory syncytial virus polypeptides: their location in the virion | Q41595401 | ||
| The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity | Q41692133 | ||
| Kinetics of synthesis of respiratory syncytial virus glycoproteins | Q44058936 | ||
| Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A | Q44255469 | ||
| Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants | Q45504141 | ||
| Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. | Q45719599 | ||
| Neuraminidase treatment of respiratory syncytial virus-infected cells or virions, but not target cells, enhances cell-cell fusion and infection | Q45722004 | ||
| Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine | Q45734744 | ||
| Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains | Q45744225 | ||
| Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein | Q45757184 | ||
| Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults | Q45768811 | ||
| Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus | Q45769917 | ||
| Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates | Q45771373 | ||
| Antigen and Polypeptide Synthesis by Temperature-sensitive Mutants of Respiratory Syncytial Virus | Q45791771 | ||
| Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine | Q45823297 | ||
| Respiratory syncytial virus polypeptides. V. The kinetics of glycoprotein synthesis | Q45828056 | ||
| Respiratory syncytial virus polypeptides. IV. The oligosaccharides of the glycoproteins | Q45828566 | ||
| Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus | Q45830099 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | infectivity | Q1662346 |
| P304 | page(s) | 10710-10718 | |
| P577 | publication date | 2009-08-05 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans | |
| P478 | volume | 83 |
| Q92219117 | A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences |
| Q35225718 | A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity |
| Q34948645 | A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles |
| Q59359689 | A sustained antiviral host response in respiratory syncytial virus infected human nasal epithelium does not prevent progeny virus production |
| Q30375413 | Acute Lung Injury Results from Innate Sensing of Viruses by an ER Stress Pathway |
| Q40388370 | An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection |
| Q36106575 | Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice |
| Q38859534 | Benzimidazole analogs inhibit respiratory syncytial virus G protein function. |
| Q35185596 | Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection |
| Q35689697 | Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells |
| Q40686849 | DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans |
| Q39143120 | Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection |
| Q90163136 | Differences in Susceptibility of Human and Mouse Macrophage Cell Lines to Respiratory Syncytial Virus Infection |
| Q39565958 | Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection |
| Q116166965 | Evidence for a functional interaction between the respiratory syncytial virus fusion and attachment proteins in the envelope of infectious virus particles |
| Q42247596 | Human airway epithelial cell cultures for modeling respiratory syncytial virus infection |
| Q35826221 | Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate |
| Q37376403 | Human respiratory syncytial virus Memphis 37 grown in HEp-2 cells causes more severe disease in lambs than virus grown in Vero cells |
| Q96131813 | IGF1R is an entry receptor for respiratory syncytial virus |
| Q38807650 | Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System |
| Q59357850 | Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection |
| Q35414495 | Inhibitors of the interferon response enhance virus replication in vitro. |
| Q36798831 | Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways |
| Q40672287 | Morphogenesis of respiratory syncytial virus in human primary nasal ciliated epithelial cells occurs at surface membrane microdomains that are distinct from cilia |
| Q35943669 | Paramyxovirus fusion and entry: multiple paths to a common end |
| Q40721454 | Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective. |
| Q92519241 | Pathogenesis of Respiratory Syncytial Virus Infection in BALB/c Mice Differs Between Intratracheal and Intranasal Inoculation |
| Q40266020 | Perinatal lamb model of respiratory syncytial virus (RSV) infection |
| Q38941405 | Preventing Cleavage of the Respiratory Syncytial Virus Attachment Protein in Vero Cells Rescues the Infectivity of Progeny Virus for Primary Human Airway Cultures |
| Q35566601 | Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years |
| Q40597801 | RSV Growth and Quantification by Microtitration and qRT-PCR Assays |
| Q35174945 | RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets |
| Q38617302 | Recent advances in the development of subunit-based RSV vaccines. |
| Q36433969 | Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein. |
| Q28551477 | Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures |
| Q26748983 | Respiratory Syncytial Virus and Cellular Stress Responses: Impact on Replication and Physiopathology |
| Q30240274 | Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment |
| Q91361642 | Respiratory syncytial virus entry and how to block it |
| Q36692791 | Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease |
| Q45358034 | Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication |
| Q115694868 | Roles of Human Respiratory Syncytial Virus Proteins in Immune Responses |
| Q37536191 | Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development |
| Q34414405 | Structure and function of respiratory syncytial virus surface glycoproteins. |
| Q33950385 | Studies of culture conditions and environmental stability of human metapneumovirus |
| Q37328584 | Targeting RSV with vaccines and small molecule drugs |
| Q115694845 | The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines |
| Q27687067 | Understanding and altering cell tropism of vesicular stomatitis virus |
Search more.